ARCHIVES

Last week’s Dow collapse wasn’t really about China or a recession. It was plain old slow growth. Biotech stocks are one remedy.

The president’s foolhardy foreign policy and wanton spending have investors fleeing to foreign exchanges. It’s time to join them.

An equity shortage, a new M&A boom, a weak dollar, and lower interest rates point to another year of big winnings on Wall Street.

The real problem isn’t the global megaretailer’s rapacious image. It’s the company’s flagging business fortunes.

Falling oil prices, a halt in interest-rate hikes, and a wave of hedge-fund buying sent the Dow above 12,000. Now they’ll take it higher.

Yes, there are out-of-control hedge-fund managers out there. But the real problems are overaggressive marketing and overeager investors.

You may think you want a Democratic Congress. But if you care about your wallet, watch what you wish for.

Fed chairman Ben Bernanke is no Alan Greenspan. For a while, that looked like bad news for the economy and stock market. Not anymore.

Former Goldman Sachs CEO Henry Paulson is a major-league hard-ass with serious Wall Street credibility. In other words, he’s just the Treasury secretary we need.

The New York Times is ditching its hallowed stock quotes and putting them online. Now they should make the whole paper digital.